Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

It is hoped that by coupling trastuzumab (Herceptin; Genentech/Roche) — a humanized monoclonal antibody (mAb) specific for the human epidermal growth factor receptor 2 (HER2; also known as ERBB2 ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

Trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta, Genentech) launched as IV-only formulations. However, subcutaneous versions have been approved and have demonstrated noninferiority to ...

The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency ...